会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Compound
    • US08846737B2
    • 2014-09-30
    • US13392206
    • 2010-08-23
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • C07D249/08
    • C07D249/08C07D401/12C07D403/12C07D405/12C07D409/12
    • There is provided a compound of formula I wherein Z is selected from N and CR22, wherein R22 is H or a bond with D; wherein D is selected from a bond, C═O, and linear or branched hydrocarbon groups having a carbon chain of from 1 to 6 carbon atoms, wherein the carbon chain optionally contains an oxy group (═O), an ether (—O—) or thioether (—S—) link, wherein R1 is selected from: triazolyl, imidazolyl, pyrimidinyl radical wherein each of R2 to R6 is independently selected from —H, NO2, halo, —CN, —N[(C═O)0-1R12][(C═O)0-1R13] and —(CH2)0-1R14, or two adjacent groups of R2 to R6, together with the carbon atoms to which they are attached, form a ring, wherein at least one of R2 to R6 is —CN, wherein (i) at least one of R2 to R6 is —(CH2)0-1R14, or (ii) at least one of R2 to R6 is —N[(C═O)0-1R12][(C═O)0-1R13], or (iii) at least two adjacent groups of R2 to R6 together with the carbon atoms to which they are attached, form a ring, or (iv) at least one of R2 to R6 is —(CH2)0-1—O—R′14, wherein R12 and R13 are independently selected from H, linear or branched hydrocarbon groups having a carbon chain of from 1 to 10 carbon atoms, or together with the atoms to which they are attached, may form a mono or bicyclic ring having from 5 to 14 ring members wherein R14 is selected from: aliphatic ring systems unsubstituted or substituted monocyclic aliphatic heterocycles; unsubstituted or substituted heteroaryl radical, and unsubstituted or substituted phenyl group; the group of formula wherein t is 1 or 2 wherein R′14 is a unsubstituted or substituted phenyl group; wherein each of R7 to R11 is independently selected from —H, NO2, halo, —O—(C1-C6)haloalkyl, (C1-C6)haloalkyl, (C1-C6)alkyl, —CN, —OH, —OPh, —OBn, -Ph, —OSO2NR15R16, —SO2R26, —SO2NR27R28, —O—(C1-C6)alkyl, —(C═O)0-1NR29R30 and —CO(O)0-1R31; wherein R15 and R16 are independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups wherein each of R26 to R31 is independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups; or any pharmaceutically acceptable salts thereof.
    • 9. 发明申请
    • COMPOUND
    • US20120238550A1
    • 2012-09-20
    • US13392206
    • 2010-08-23
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • Lok Wai Lawrence WooChristian BubertPaul Michael WoodAurélien PuteyAtul PurohitBarry Victor Lloyd Potter
    • A61K31/4196C07D409/12C07D403/12A61K31/55C07D401/12A61P35/00C07D413/12A61K31/5377A61K31/496A61K31/4439C07D405/12C07D249/08A61K31/454
    • C07D249/08C07D401/12C07D403/12C07D405/12C07D409/12
    • There is provided a compound of formula I wherein Z is selected from N and CR22, wherein R22 is H or a bond with D; wherein D is selected from a bond, C═O, and linear or branched hydrocarbon groups having a carbon chain of from 1 to 6 carbon atoms, wherein the carbon chain optionally contains an oxy group (═O), an ether (—O—) or thioether (—S—) link, wherein R1 is selected from: triazolyl, imidazolyl, pyrimidinyl radical wherein each of R2 to R6 is independently selected from —H, NO2, halo, —CN, —N[(C═O)0-1R12][(C═O)0-1R13] and —(CH2)0-1R14, or two adjacent groups of R2 to R6, together with the carbon atoms to which they are attached, form a ring, wherein at least one of R2 to R6 is —CN, wherein (i) at least one of R2 to R6 is —(CH2)0-1R14, or (ii) at least one of R2 to R6 is —N[(C═O)0-1R12][(C═O)0-1R13], or (iii) at least two adjacent groups of R2 to R6 together with the carbon atoms to which they are attached, form a ring, or (iv) at least one of R2 to R6 is —(CH2)0-1—O—R′14, wherein R12 and R13 are independently selected from H, linear or branched hydrocarbon groups having a carbon chain of from 1 to 10 carbon atoms, or together with the atoms to which they are attached, may form a mono or bicyclic ring having from 5 to 14 ring members wherein R14 is selected from: aliphatic ring systems unsubstituted or substituted monocyclic aliphatic heterocycles; unsubstituted or substituted heteroaryl radical, and unsubstituted or substituted phenyl group; the group of formula wherein t is 1 or 2 wherein R′14 is a unsubstituted or substituted phenyl group; wherein each of R7 to R11 is independently selected from —H, NO2, halo, —O—(C1-C6)haloalkyl, (C1-C6)haloalkyl, (C1-C6)alkyl, —CN, —OH, —OPh, —OBn, -Ph, —OSO2NR15R16, —SO2R26, —SO2NR27R28, —O—(C1-C6)alkyl, —(C═O)0-1NR29R30 and —CO(O)0-1R31; wherein R15 and R16 are independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups wherein each of R26 to R31 is independently selected from H, alkyl, cycloalkyl, alkenyl, acyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl optionally contain one or more hetero atoms or groups; or any pharmaceutically acceptable salts thereof.
    • 10. 发明授权
    • Oestrogen-17-sulphamates as inhibitors of steroid sulphatase
    • 雌激素-17-磺酰胺酸盐作为类固醇硫酸酯酶的抑制剂
    • US08030296B2
    • 2011-10-04
    • US11368367
    • 2006-03-03
    • Barry Victor Lloyd PotterMichael John ReedLok Wai Lawrence WooHatem HejazBertrand LeblondMatthew Paul LeeseAtul Purohit
    • Barry Victor Lloyd PotterMichael John ReedLok Wai Lawrence WooHatem HejazBertrand LeblondMatthew Paul LeeseAtul Purohit
    • A61K31/56C07J1/00
    • A61K31/565A61K31/37
    • There is provided a compound of Formula I wherein X is a ring system; R1 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; R2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein when X is a steroidal structure and both of R1 and R2 are sulphamate groups, the steroidal ring system (X) represents an oestrogen; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth. There is also provided a compound of Formula VIII wherein R2 is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.
    • 提供式I的化合物,其中X是环系; R1是氨基磺酸酯基,膦酸酯基,硫代膦酸酯基,磺酸酯基或磺酰胺基中的任何一个; R2是氨基磺酸酯基,膦酸酯基,硫代膦酸酯基,磺酸酯基或磺酰胺基中的任何一个; 其中当X是甾体结构且R 1和R 2均为氨基磺酸酯基团时,甾体环体系(X)代表雌激素; 并且其中所述化合物能够抑制类固醇硫酸酯酶(STS)活性和/或能够充当细胞循环的调节剂和/或作为凋亡调节剂和/或细胞生长调节剂。 还提供了式VIII的化合物,其中R 2是氨基磺酸酯基,膦酸酯基,硫代膦酸酯基,磺酸酯基或磺酰胺基中的任何一个; 并且其中所述化合物能够抑制类固醇硫酸酯酶(STS)活性和/或能够充当细胞循环的调节剂和/或作为凋亡调节剂和/或细胞生长调节剂。